American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 366-369 , March 2008

Critical Missing Data on Erythropoiesis-Stimulating Agents in CKD: First Beat Placebo

  • Marc A. Pfeffer, MD, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Marc A. Pfeffer, MD, Cardiovascular Division, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115.

References 

  1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension (Results in patients with diastolic blood pressures averaging 115 through 129 mm HgMz). JAMA. 1967;202:1028–1034
  2. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively- designed overviews of randomised trials. Lancet. 2003;362:1527–1535
  3. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure (Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)). N Engl J Med. 1987;316:1429–1435
  4. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293–302
  5. Pfeffer MA, Braunwald E, Moyé LA, et al. The SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction (Results of the survival and ventricular enlargement trial). N Engl J Med. 1992;327:669–677
  6. Pedersen TR, Kjekshus J, Berg K, Haghfelt T, et al. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–1389
  7. Sacks FM, Pfeffer MA, Moye LA, et al. Cholesterol and Recurrent Events Trial investigators The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001–1009
  8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–1357
  9. Shepherd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301–1307
  10. Downs JR, Clearfield M, Weis S, et al. Air Force/Texas Coronary Atherosclerosis Prevention Study Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–1622
  11. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
  12. Wanner C, Krane V, Marz W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238–248
  13. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet. 2002;360:1623–1630
  14. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med. 2007;357:2248–2261
  15. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504
  16. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425–1435
  17. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin (Results of a combined phase I and II clinical trial). N Engl J Med. 1987;316:73–78
  18. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: Association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2004;19:121–132
  19. Steinbrook R. Haemoglobin concentrations in chronic kidney disease. Lancet. 2006;368:2191–2193
  20. Ingelfinger JR. Through the looking glass: Anemia guidelines, vested interests, and distortions. Clin J Am Soc Nephrol. 2007;2:415–417
  21. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–2084
  22. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085–2098
  23. Levin A. Understanding recent haemoglobin trials in CKD: Methods and lesson learned from CREATE and CHOIR. Nephrol Dial Transplant. 2007;22:309–312
  24. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis. Lancet. 2007;369:381–388
  25. Federal Drug Administration: Answers. http://www.fda.gov/bbs/topics/ANSWERS/ANS00103.htmlAccessed January 8, 2008
  26. Mix TC, Brenner RM, Cooper ME, et al. Rationale—Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. Am Heart J. 2005;149:408–413
  27. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. Rev Cardiovasc Med. 2005;6(suppl 3):S35–S41
  28. Strippoli GF, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Haemoglobin targets: We were wrong, time to move on. Lancet. 2007;369:346–350
  29. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. N Engl J Med. 2007;356:959–961

PII: S0272-6386(08)00041-3

doi: 10.1053/j.ajkd.2008.01.003

American Journal of Kidney Diseases
Volume 51, Issue 3 , Pages 366-369 , March 2008

Article Tools